APA (7th ed.) Citation

Y, D., & P, S. (2025). ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma. Annals of surgical oncology, 32(10), 7268. https://doi.org/10.1245/s10434-025-18109-8

Chicago Style (17th ed.) Citation

Y, Dong, and Starlinger P. "ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma." Annals of Surgical Oncology 32, no. 10 (2025): 7268. https://doi.org/10.1245/s10434-025-18109-8.

MLA (9th ed.) Citation

Y, Dong, and Starlinger P. "ASO Author Reflections: Real-World Outcomes of Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab for Surgical Conversion of Borderline Resectable Cholangiocarcinoma." Annals of Surgical Oncology, vol. 32, no. 10, 2025, p. 7268, https://doi.org/10.1245/s10434-025-18109-8.